Hims & Hers Health (NYSE:HIMS) Price Target Raised to $27.00

Hims & Hers Health (NYSE:HIMS) had its target price lifted by investment analysts at Citigroup from $25.00 to $27.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “sell” rating on the stock. Citigroup’s price objective suggests a potential downside of 47.44% from the stock’s current price.

HIMS has been the topic of a number of other research reports. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler increased their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $30.67.

Hims & Hers Health Trading Up 4.2 %

Shares of NYSE:HIMS opened at $51.37 on Tuesday. The company has a 50 day moving average of $35.45 and a 200 day moving average of $26.08. Hims & Hers Health has a 12 month low of $9.67 and a 12 month high of $72.98. The stock has a market cap of $11.22 billion, a P/E ratio of 116.75 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at approximately $5,692,221.49. The trade was a 56.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,080,275 shares of company stock valued at $37,247,354 in the last 90 days. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HIMS. Main Management ETF Advisors LLC bought a new position in Hims & Hers Health in the third quarter worth $672,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Hims & Hers Health in the 3rd quarter worth about $604,000. Royce & Associates LP lifted its position in Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the period. Versor Investments LP purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $634,000. Finally, International Assets Investment Management LLC bought a new stake in Hims & Hers Health during the third quarter worth about $6,790,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.